Batch dependent - please inquire should you have specific requirements.
Buffer
500mM Histidine, 100mM NaCl, 0.02% Tween80, pH6.0
Preservative
None
Storage
Store at -80°C. Avoid repeated freeze/thaw cycles
Antigen Description
Human papillomavirus (HPV) is a DNA virus from the papillomavirus family that is capable of infecting humans. Like all papillomaviruses, HPVs establish productive infections only in keratinocytes of the skin or mucous membranes. L1 is a major capsid protein of human papilloma virus. Infection with specific types of HPV has been associated with an increased risk of developing cervical neoplasia. Does not bind DNA.
Keywords
HPV 11 L1; L1; Major capsid protein L1
Citations
Publication ()
Have you cited DAGF-228 in a publication? Let us know and earn a reward for your research.
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization
McCormick RA, Ralbovsky NM, Gilbraith W, Smith JP, Booksh KS
Applications: Unspecified applicationReactive species: Unspecified reactive species
"Abstract: Analysis of virus-like particles (VLPs) is an essential task in optimizing their implementation as vaccine antigens for virus-initiated diseases. Interrogating VLP collections for elasticity by probing with a rigid atomic force microscopy (AFM) tip is a potential method for determining VLP morphological changes. During VLP morphological change, it is not expected that all VLPs would be in the same state. This leads to the open question of whether VLPs may change in a continuous or stepwise fashion. For continuous change, the statistical distribution of observed VLP properties would be expected as a single distribution, while stepwise change would lead to a multimodal distribution of properties. This study presents the application of a Gaussian mixture model (GMM), fit by the Expectation-Maximization (EM) algorithm, to identify different states of VLP morphological change observed by AFM imaging."Article snippet: HPV type 11 VLPs were also purchased from Creative Diagnostics (Shirley, NY, USA) for additional analysis.
Background
Papillomaviruses are viruses that cause squamous epithelial and fibroepithelial tumors in their specific host species. In humans, human papillomaviruses (HPVs) can lead to both benign and malignant cell overgrowth, resulting in a wide range of clinical manifestations from genital warts to cervical cancer. HPV-11 belongs to the Papillomaviridae family and is classified as a low-risk HPV type. It is primarily transmitted through sexual contact, and infection with HPV-11 can lead to the development of genital warts, also known as condylomata acuminata. These warts can appear on the genitals, anus, or surrounding areas and are typically non-cancerous. However, it is important to note that HPV-11 infection increases the risk of developing certain types of cancer, such as recurrent respiratory papillomatosis (RRP) in children and adults.
The L1 protein is one of the major structural proteins of HPV-11 and is responsible for the formation of virus-like particles (VLPs). VLPs consist of 36 copies of L1 protein arranged into 72 pentamers or capsomeres, forming structures that are immunologically similar to native virions. The VLPs induce a type-specific immune response, with minor cross-neutralization observed mainly between closely related HPV types. Structural analysis revealed the presence of hypervariable loops on the outer surface of the capsid. Most HPV-neutralizing monoclonal antibodies identified to date are type-specific and recognize conformational epitopes within these surface-exposed hypervariable loops of the L1 protein.
Figure 1. Assembly of L1 VLP vs. assembly of authentic virus. (Source: Lowy, D. R., 2016)
VLPs are self-assembling structures that mimic the natural virus but are non-infectious since they do not contain the viral genome. The HPV type 11 L1 protein is used in the production of VLP-based vaccines, such as the widely known HPV vaccines, which provide protection against HPV infection and associated diseases. HPV type 11 L1 VLPs serve as antigens that stimulate the immune system to produce specific antibodies against HPV. These antibodies can help prevent subsequent HPV infections by neutralizing the virus, thereby reducing the risk of developing genital warts and potentially decreasing the likelihood of HPV-related cancers. The use of HPV vaccines has proven to be highly effective in preventing HPV infections and associated diseases.
Alternative Names
Recombinant HPV type 11 L1 protein (VLP) Recombinant HPV 11 L1 protein (VLP)
References
1. Lowy D R. HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. The Journal of Clinical Investigation. 2016, 126(1): 5-11.
My Review for Recombinant Human Papilloma Virus type 11 L1 protein (VLP)
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles
The L1 coat protein of human papillomavirus type 11 (HPV-11) was expressed in Sf-9 insect cells with the recombinant baculovirus vector Ac11L1. Viruslike particles (VLPs) were identified by electron microscopy in the nucleus and cytoplasm of Sf-9 cells infected with Ac11L1. The L1 protein was purified from Ac11L1-infected insect cells. The purified protein spontaneously assembled in vitro into various aggregates, including particles appearing similar to empty virions. Reaction of VLP-containing insect cell extracts with antisera directed against either denatured or nondenatured capsid epitopes in Western blot (immunoblot) and immuno-dot blot assays suggested that conformational epitopes present in native HPV-11 infectious virions were also present on the baculovirus-produced HPV-11 VLPs. Immuno-dot blot assays using human sera obtained from individuals with biopsy-proven condyloma acuminatum correlated closely with results previously obtained in HPV-11 whole virus particle-based enzyme-linked immunosorbent assays. These morphologic and immunologic similarities to native HPV-11 virions suggest that recombinant VLPs produced in the baculovirus system may be useful in seroepidemiology and pathogenesis studies of genital HPV infection and that they may also be potential candidates for vaccine development.
Malignancy Associated with Low-Risk HPV6 and HPV11: A Systematic Review and Implications for Cancer Prevention
Cancers
Authors: Silva L L, Teles A M, Santos J M O, et al.
High-risk human papillomavirus (HPV) is etiologically related to cervical cancer, other anogenital cancers and oropharyngeal carcinomas. Low-risk HPV, especially HPV6 and HPV11, cause genital warts and laryngeal papillomas. However, the accumulating data suggests that HPV6 and HPV11 may cause malignant lesions at non-cervical anatomic sites. This review aims to estimate the proportions of single and dual HPV6/11 infections in multiple cancers reported in the last 10 years in the Cochrane, Embasa and PubMed databases. Secondly, the genomes of HPV6/11 were compared with the most common high-risk genotype, HPV16, to determine the similarities and differences. A total of 11 articles were selected, including between one and 334 HPV+ cancer patients. The frequencies of single or dual HPV6/11 infections ranged between 0–5.5% for penile and 0–87.5% for laryngeal cancers and were null for vulvar, vaginal and oral cancers. The genomic similarities between HPV6/11 and HPV16 mainly involved the E7 gene, indicating a limited ability to block cell differentiation. The presence of single or dual HPV6/11 infections in variable proportions of penile and laryngeal cancers support the vaccination strategies that cover these genotypes, not only for preventing genital warts but also for cancer prevention. Other risk factors and co-carcinogens are likely to participate in epithelial carcinogenesis associated with low-risk HPV.
COA
Publication 
Figure 1. Assembly of L1 VLP vs. assembly of authentic virus.
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
Loading ......
.jpg)
